NCPA highlights importance of medication adherence with new resources for pharmacists
ALEXANDRIA, Va. — The National Community Pharmacists Association has published a special edition of its America’s Pharmacist magazine, which exclusively focuses on medication adherence.
The NCPA said the issue examines how Medicare now is using medication adherence metrics to calculate Medicare Part D plan star ratings, including Medicare Advantage and Medicare Part D plans; offers an independent pharmacist’s view on why mail order and adherence don’t mix ("Adherence is not in the Mail"); and looks at a new adherence metric of pharmacy performance ("Equipped for Adherence").
In addition to the publication, NCPA also recently launched Stick2thescript.org, a new site that provides pharmacists and other healthcare providers with a comprehensive resource of tools, programs and other resources to use with patients to help them understand the goals and outcomes of their prescription regimen, manage their chronic condition(s) and take their medications as directed.
"NCPA is proactively tackling this challenge and has launched a full-court press on the problem of nonadherence," NCPA CEO Douglas Hoey said. "The community pharmacist is the expert team member who can effectively identify and resolve medication issues. By identifying solutions and providing concrete actions and resources, we believe pharmacists are putting us one step closer to solving this expensive and unnecessary healthcare crisis."
CHPA recognized for its ‘Up and Away and Out of Sight’ PSA
WASHINGTON — The Consumer Healthcare Product’s Association’s Educational Foundation was recognized with two awards for its "Up and Away and Out of Sight" campaign, CHPA shared in an e-newsletter Tuesday.
The educational program launched in partnership with the Center for Disease Control and Prevention in December 2011 and reminds families of the importance of safe medicine storage. The CDC submitted the "Up and Away and Out of Sight" educational program into its "Center Level" award competition (an internal competition) and won the “Plain Language Communications” award. This award commends campaigns that include language a listener or reader can understand the first time they hear or read it. "Up and Away and Out of Sight" now is being advanced to the next CDC-wide competition, and if it wins it will move on to the Department of Health and Human Services-wide competition.
In addition, "Up and Away and Out of Sight" won a PRSA Bronze Anvil Award of Commendation from the Public Relations Society of America. Specifically, this award recognizes the launch of UpandAway.org, a new website which serves as the online hub and houses all the multimedia resources and engagement tools developed for parents and caregivers. According to PRSA, this year’s competition drew a total of 784 entries. Of those, only 83 organizations were selected as Bronze Anvil Award of Commendation winners.
NAD recommends Lunada tone down claims for menopausal supplement
NEW YORK — The National Advertising Division of the Council of Better Business Bureaus on Wednesday recommended Lunada Biomedical modify or discontinue a certain range of advertising claims for Amberen, a dietary supplement promoted to menopausal women.
NAD noted in its decision that Lunada had voluntarily discontinued certain claims, including claims that relief is "complete," "fast," that Amberen is an "all-in-one solution," and that Amberen can achieve "balanced production and circulation of hormones throughout your body" and support "the optimal function of your vital organs. Energy metabolism is soon restored. Suddenly you feel younger!"
NAD also noted Lunada’s decision to discontinue making its claim that the ingredients in Amberen are on the Food and Drug Administration’s Generally Recognized as Safe list.
NAD shared several concerns around the disconnect between a study purportedly supporting Lunada’s claims and the advertising at issue. NAD recommended that Lunada discontinue claims that Amberen relieves "night sweats," "moodiness" and "inability to concentrate." Further, NAD cautioned the advertiser against suggesting or implying that the product provides complete or near-complete relief of symptoms.
NAD determined the company could support claims related to its proprietary technology, as well as the claim that Amberen could lessen various symptoms of menopause.
NAD is an investigative unit of the advertising industry’s system of self-regulation and administered by the Council of Better Business Bureaus. As a part of its ongoing monitoring program and in conjunction with NAD’s initiative with the Council for Responsible Nutrition designed to expand review of advertising claims for dietary supplements, NAD requested the advertiser provide substantiation for claims made in print and Internet advertising.